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1. Introduction
Ownership of dialysis facilities has shifted over the past decade. Where nonprofit organiza‐
tions once managed these facilities, large companies now have control. Shareholders of
these companies are primarily interested in the profitability of their investments rather than
the well-being of the patients being treated. Market forces rather than scientific inquiry now
drive much of the research related to end-stage renal disease (ESRD). These developments
have created ethical dilemmas for physicians. This editorial describes some of these ethical
challenges and asserts that the doctor–patient relationship and its ethical imperatives are
more important than company profit and loss statements.
2. Dialysis
2.1. History
Gaining proper access to the human circulatory system is required to transport blood from
the patient to the artificial kidney and back again during hemodialysis. In 1943, Dr. Willem
J. Kolff first encountered the problem of vascular access for hemodialysis [1]. After 34 days
of puncturing readily accessible blood vessels, he failed to enter the bloodstream. As a con‐
sequence, his patient died. The chronic hemodialysis era began almost 20 years later, when
Quinton and Scribner introduced the first external arteriovenous shunt constructed of Tef‐
lon, which allowed repeated access to the vascular system [2].
In 1966 a major breakthrough in vascular access surgery was achieved with the introduction
of the first endogenous fistula by Brescia and Cimino [3, 4]. They created a side-to-side anas‐
tomosis between the radial artery and cephalic vein, which ensured functional vascular ac‐
cess. Later, brachiocephalic and transposed brachiobasilic fistulae were constructed,
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followed by the emergence of various prosthetic grafts as an alternative to native fistula.
Polytetrafluoroethylene is now the most frequently used graft material. Nevertheless, vascu‐
lar access-related complications are still often responsible for patient hospitalization, mor‐
bidity, and even mortality [5, 6]. Facility preference and variations in approach to vascular
access practice still seem to be major determinants of vascular access success or failure [7].
2.2. Costs
Therapy for ESRD patients is expensive and therefore impracticable in some countries. Even
some of the more affluent countries do not provide readily accessible free treatment to all
renal failure patients; in 2002, 58% of hemodialysis providers in the United Kingdom had no
vacant staffed slots for new patients [8]. In the United States, discussion has been ongoing as
to whether the Medicare system, which provides public funding for patients with renal fail‐
ure, should be modified as post-World War 2 ‘baby boomers’ reach old age [9, 10].
Patients should be allowed time off from their jobs for dialysis treatment and extra time off
when complications arise. Paid leave for medical treatment requires cooperation from gov‐
ernment and employers. [Remark 3]
This chapter sets out our view of the minimum standards required to provide sufficient care
for patients with ESRD. These standards may require modification in response to local cir‐
cumstances or new research data, but we hope that they will help doctors in all countries to
argue for sufficient resources for their patients with ESRD.
[Remark 3] Timing
One ethical issue to be discussed involves the timing of dialysis initiation. Traditional indi‐
cators for starting dialysis included the presence of signs and symptoms of uremia in combi‐
nation with pertinent results of biochemical analyses of serum and plasma [13]. However,
several observational cohort and case–control studies have suggested that early initiation of
dialysis may improve patients’ survival, quality of life, and capacity for employment while
decreasing complications [14, 15]. Although such studies were potentially limited by biases
related to lead time, patient selection, and referral time, the clinical practice guidelines that
were in use in the late 1990s [16] recommended the commencement of dialysis when the di‐
rectly measured or calculated (estimated) glomerular filtration rate was higher than the val‐
ues previously targeted for the initiation of dialysis. However, more recent observational
data have suggested that starting dialysis early may in fact be harmful [17, 18]. We assert
that if early dialysis benefits patients, it should be used, and, by contrast, if it causes harm, it
should not be used, in accordance with the principle of nonmaleficence. [Remark 1]
3. Ethical issues
3.1. Fair selection
Ideally all patients who can benefit from dialysis should be offered it free of charge. Howev‐
er, many countries cannot afford the substantial cost of treating all patients with renal fail‐
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ure by dialysis and transplantation [19]. The problem for poorer countries is exacerbated by
their higher incidence of renal failure. The aim of patient selection for dialysis should be to
use scarce resources to provide maximum benefit. This implies that patients should be se‐
lected who are likely to enjoy a good quality of life as a result of treatment. Selection should
not be influenced by race, color, creed, caste, or political affiliation. Age per se should not be
a selection criterion. Since comorbidities are more likely in elderly patients, the majority of
patients selected for dialysis is likely to be younger. However, many elderly patients may
also enjoy a good quality of life [20].
If the only way of obtaining regular dialysis is by payment into a private medical insurance
system, patients able and willing to pay the costs should be allowed to do so. No ‘waiting
list’ for dialysis should be maintained, nor should any patient be assigned to a therapy
known to be inappropriate to meet his or her needs.
3.2. Patient choice
Patient preference plays a part in the selection of the dialysis modality, but this is often over‐
ridden by other factors, including availability of hemodialysis stations, difficulty with vas‐
cular access placement or preservation, and failure of peritoneal dialysis techniques. In
addition, a certain proportion of patients presents late as ‘uremic emergencies’. Patients
must be informed of the advantages and drawbacks of the various available types of dialy‐
sis, the prognosis with and without dialysis treatment, and its effect on quality of life so that
they can make informed choices on the basis of current information [21, 22]. Treatment deci‐
sions should be consistent with the goals of regaining or maintaining active employment
and maximizing rehabilitation of patients into society.
[Remark 3]Privacy and patient rights
The processes of diagnosis, consultation, surgery for vascular access, and dialysis treatment
should be conducted in ways that protect patient privacy. They should know the identity of
the physicians, nurses, and others involved in their care. They are entitled to (i) refuse a rec‐
ommended type of treatment and be informed of the medical consequences of this action;
(ii) consent or decline to participate in research studies after being fully informed of their
purpose [22]; (iii) be treated with respect, dignity, courtesy, compassion, and cultural sensi‐
tivity; (iv) have any treatment, possible complications, and self-care requirements explained
in an understandable manner, with sufficient time to ask questions and receive answers; (v)
be allowed to obtain a second opinion for a given treatment and ask for consultation with
another physician; (vi) designate relatives or friends to be kept informed of their medical
condition; (vii) be informed about names, dosages, indications, and adverse reactions of all
prescribed medications [21]; and (viii) be fully informed about the results of laboratory anal‐
yses and any tests they undergo. Gardner et al. demonstrated that a well-developed single-
item measure can be appropriate in avoiding common methods variance, which is often a
problem with psychological measures that require respondent self-reports of attitudes, be‐
liefs, perceptions, and the like [23]. [Remark 4] Notwithstanding this limitation, we suggest
that patients’ beliefs about their illness and treatment are important for their sense of (glob‐
al) autonomy and self-esteem. Correlations have been identified between appropriate medi‐
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cal management, time on dialysis, and positive self-perception of health with better
problem-solving ability and higher autonomy, but lower sociotropic personality styles. [Re‐
mark 5]
3.3. Loss of autonomy
A few studies have been published on the number of patients who decided to withdraw
from dialysis once treatment was initiated [11, 12]. [Remark 3] Loss of autonomy was one of
the most important reasons for patients to decline dialysis treatment. Patients who chose not
to start dialysis were reluctant to give up their freedom and become dependent on medical
treatment. They would rather live for a shorter time with more freedom, than live longer
with the limitations of a comprehensive treatment such as dialysis. “You are going to die
anyway … and making a trip to the hospital 3 times per week, already being tired and ex‐
hausted, and while basically handing your life to others, is such a great deal of effort, I can’t
do that!” [Remark 6]
3.4. Quality of life
One of the most important factors in the choice of treatment in patients with ESRD is quality
of life. For many patients, the challenges of living with chronic kidney disease may not pre‐
vent them from appreciating the small things in life. Several studies have demonstrated that
participation in an exercise program either before or during dialysis can improve quality of
life. [Remark 7]
ESRD and its treatments may have a negative impact on quality of life. Nephrologists, like
all physicians, must offer their patients all reasonable treatment options. When dialysis is (or
is not) a reasonable option is an important ethical issue. The justification for dialysis, like
any life-sustaining treatment, is that it prolongs life for a patient who either wishes to live
longer or, if cognitively impaired, would (in the opinion of others) be likely to benefit from
extension of life.
Case Against Dialysis [Remark 8]
The following section focuses on patients with advanced dementia or severe and irreversible
brain injury who were no longer capable of enjoying life, and hence gained no benefit from
dialysis. Guidelines are presented for withholding and withdrawing dialysis and sugges‐
tions are offered to help nephrologists avoid causing harm when the patient’s family de‐
mands that dialysis be performed [24]. [Remark 9]
3.5. Dialysis refusal
The Medical Code of Ethics states that patients have the right to refuse medical treatment,
and that physicians must accept and respect these decisions. Physicians must guarantee that
patients die with dignity while not prolonging or shortening their lives. [Remark 3] Many
patients have reported enjoying life and have expressed a desire to live for as long as possi‐
ble, but not at any price. In one study, however, many patients chose not to start dialysis.
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Most patients who declined dialysis had made the decision before they received information
on the treatment and would not have even considered the possibility. These patients indicat‐
ed that they would have considered treatment when they were younger, in better health, or
in severe pain [25].
[Remark 3]In another study, patients decided to discontinue dialysis because of an unac‐
ceptable quality of life, depression, and a chronic failure to thrive. Health professionals must
support end-of-life decision-making using an ethical decision framework [26].
3.6. Age-associated decrease in vitality
Some patients decline dialysis due to an age-associated decrease in vitality. Most patients
who declined dialysis reported that they had good lives. However, the discrepancy between
their former active lives and their present lives was large. They were incapable of doing
many things. Patients noted that they had already had to give up so much in life, and that
adding dialysis treatment would be too much. Patients who refused dialysis seemed to be
able to face the finiteness of life. They all spoke about the good life they had lived. The seri‐
ous disruption of life caused by dialysis was unacceptable to them.
A few patients indicated that their overall ability to plan and organize significantly deterio‐
rated with age. As a result, making doctor appointments and arranging to get there in time
required too much energy. For most patients, the decision not to pursue dialysis treatment
was not well-considered, but in their perception, it was the only option. For those patients
with relatively good health, dialysis seemed like a natural decision. Earlier studies showed a
worse quality of life in elderly dialysis patients with a higher number of comorbidities and
no better survival rates than in patients not undergoing treatment [27–29]. The extent to
which elderly patients with poor health status may benefit from this treatment is therefore
questionable.
For most patients who declined dialysis, the anticipated loss of autonomy in combination
with their age-associated decrease in vitality fueled their refusal. Many patients declined di‐
alysis due to a preference to live from day to day without stress related to illness and treat‐
ment. In this study, patients who declined dialysis treatment were mostly men. [Remark 10]
Previous research on the impact of gender on the initiation of dialysis was not available.
However, patient withdrawal after treatment initiation has been demonstrated as more com‐
mon among women than men [30].
4. Other issues
4.1. Social support
Lack of social support is a significant predictor of mortality, even when a large number of
medical variables are controlled.Remark7 Findings of several studies are consistent with the
view that social support is an important factor in general health outcome and adjustment to
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chronic and acute illness [31]. Therefore, health care personnel should provide information
with honesty to help patients to predict their quality of life and death. Support for the pa‐
tient and family during the end-of-life period should be multidisciplinary, with clear and
timely communication between all members of the team [26]. Understanding the importance
of social support at the start of dialysis treatment and its association with survival and well-
being may have important clinical benefits for patients with ESRD. Clinical practice can then
be geared toward the promotion or improvement of patients' support networks. Social sup‐
port affects health through behavioral, physiological, and psychological mechanisms [32].
Provision of social support can be emotional or tangible. It may involve sharing information
or giving advice. The characteristics of ESRD and its treatments are functionally debilitating,
affecting social relationships and activities of daily living [33]. Diverse expectations regard‐
ing social support between patients and their families and friends may exist. While patients
may hope to minimize lifestyle changes despite the restrictions of dialysis, people in their
support network may be unaware or unsure of how to cope with the patients’ treatment and
dietary needs [34]. Feeling socially isolated can induce stress and anxiety, which in turn can
produce physiological changes, such as a compromised immune system [28]. If prolonged,
these changes could lead to higher morbidity and mortality [35]. Depression has also been
associated with lower levels of perceived social support in HD patients [36].
The fact that patients on dialysis require different types of social support has important clin‐
ical implications. Clinical care providers may tailor intervention programs to improve social
support based on patients’ needs, making recommendations to appropriate programs like
self-help groups [37] or psychoeducational programs [35–38] designed to promote self-effi‐
cacy in coping with dialysis. ESRD patients undergoing dialysis require different types of
social support depending on their social environment and severity of the illness. Future
studies may provide a longitudinal assessment with several points of data collection, chart‐
ing possible changes in social support needs since the start of dialysis and their association
with survival.
4.2. Transport and facilities
For the majority of patients, one-way travel time to receive dialysis should be less than 30
minutes. Ideally, dialysis units and their satellites should be distributed throughout the
country. If the nearest unit is far from a patient’s home, transportation costs should be fully
reimbursed [19]. The dialysis unit should be designed for comfort while waiting as well as
during treatment. Communication regarding appointments and medical advice should be
readily available.
Approximately half of ESRD patients in developed countries have their own transportation,
while the other half are dependent on ambulance or hospital transportation services [20].
Transport should aim to make the dialysis day as short as possible. Each dialysis unit
should have nurses trained in renal care, cardiac or respiratory emergencies, and hemodial‐
ysis procedures. Each dialysis station can treat up to four ESRD patients per day, but time
must be allowed for cleaning and disinfecting the dialysis room and machines.
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Hemodialysis satellites facilities need good road communications and parking facilities.
Each dialysis station should have a dialysis machine that measures and controls ultrafiltra‐
tion, a weighing bed or armchair for the patient, an abundant oxygen supply, and adequate
lighting. Testing for viral hepatitis should be performed every 3 months in all patients.
HBsAg-positive patients should ideally be dialyzed in a separate dialysis area with dedicat‐
ed hemodialysis machines, but in practice a dedicated side room and equipment are often
used. Patients with hepatitis C virus and HIV carriers can be treated in regular dialysis
units, but should be dialyzed with designated hemodialysis machines [22].
4.3. Dose
A strong correlation has been demonstrated between hemodialysis dose and patient mor‐
tality  and  morbidity  [39].  Hemodialysis  adequacy  and  delivered  hemodialysis  dose
should  therefore  be  assessed  regularly,  at  least  once  a  month,  in  both  adults  and  chil‐
dren. A stable single-pool Kt/V>1.2 should be provided for at least 90% of patients. More
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